Silverman, Stuart L.; Raisz, Lawrence G.
March 2008
Endocrine Today;3/10/2008, Vol. 6 Issue 4, p13
The article provides views on whether patients with osteoporosis need a thorough dental exam before starting bisphosphonate therapy. Doctor Stuart L. Silverman, attending physician at Cedars-Sinai Medical Center, stated that a dental exam is not needed if risk factors are not present. Doctor Lawrence G. Raisz, director of the University of Connecticut Center for Osteoporosis, countered this by stating that a dental consultation is needed before treatment with bisphosphonate.


Related Articles

  • Alendronate given for 4 years continues to increase bone density.  // Geriatrics;Jan98, Vol. 53 Issue 1, p68 

    Focuses on the bisphosphonate alendronate sodium (Fosamax) and its ability to promote bone density in postmenopausal women with osteoporosis. Details on a two-year extension study conducted by Ronald Emkey, M.D., director of the Bone Research Center, Reading Hospital and Medical Center in West...

  • Erratum to: Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI study. Sakai, A.; Ikeda, S.; Okimoto, N.; Matsumoto, H.; Teshima, K.; Okazaki, Y.; Fukuda, F.; Arita, S.; Tsurukami, H.; Nagashima, M.; Yoshioka, T. // Osteoporosis International;Oct2014, Vol. 25 Issue 10, p2505 

    A correction to the article "Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: The BP-MUSASHI study" that was published in a previous issue is presented.

  • Bisphosphonate therapy: when not to monitor BMD. Sharma, Umang; Stevermer, James J. // Journal of Family Practice;Nov2009, Vol. 58 Issue 11, p594 

    The article discusses a case study of a 68 year old woman diagnosed with osteoporosis. The patient had experienced a DXA scan screening in the previous year and taken bisphosphonate. It is cited that using DXA scan to distinguish osteoporosis is a cost-saving approach in older women. It also...

  • Etidronate thwarts osteoporosis secondary to corticosteroids.  // Geriatrics;Sep97, Vol. 52 Issue 9, p96 

    Reveals that the intermittent cyclical theraphy (ICT) with the bisphosphonate etidronate disodium drugs can prevent corticosteroids-induced osteoporosis according to a Canadian collaborative trial. Study that supported this claim; Advantage of this drug compared to other drugs of choice.

  • Bisphosphonate shows benefit for established osteoporosis in 1 year.  // Geriatrics;Jan2000, Vol. 55 Issue 1, p32 

    Details a study that examined the use of risedronate (Actonel) in persons with osteoporosis conducted by the Vertebral Efficacy with Risedronate Therapy study group. Advantages of using bisphosphonate in postmenopausal women with osteoporosis; Methodology; Results; Conclusion; Implications.

  • Efficacy and safety of a bisphosphonate dosed once weekly . Baran, Daniel // Geriatrics;Mar2001, Vol. 56 Issue 3, p28 

    Evaluates the efficacy and safety of biphosphonate alendronate in treating and preventing postmenopausal osteoporosis. Clinical impact of osteoporosis; Steps in a bone remodeling cycle; Evaluation of other antiresorptive agents.

  • Bisphosphonates: Safety and Efficacy in the Treatment and Prevention of Osteoporosis. Greenspan, Susan L.; Harris, Steven T.; Bone, Henry; Miller, Paul D.; Orwoll, Eric S.; Watts, Nelson B.; Rosen, Clifford J. // American Family Physician;5/1/2000, Vol. 61 Issue 9, p2731 

    Evaluates the efficacy and safety of bisphosphonates in treating and preventing osteoporosis. Background on bisphosphonates; Prevention of bone loss in postmenopausal osteoporosis; Treatment of established postmenopausal osteoporosis.

  • Treating glucocorticoid-induced osteoporosis.  // Critical Care Alert;Jun2009 Pharmacology, p2 

    The article discusses a new study from "Lancet" which suggests that a once-yearly infusion of zoledronic acid is as effective as daily risedronate for patients with glucocorticoid-induced osteoporosis.

  • Effect of oral alendronate on postmenopausal osteoporosis.  // American Family Physician;4/1/1996, Vol. 53 Issue 5, p1848 

    Focuses on the effects of oral alendronate, a bisphosphonate, on bone mineral density and fractures in women with postmenopausal osteoporosis. Methodology of study; Number of participants; Authors' conclusion; Increase in bone density; Study from U.A. Liberman in the New England Journal of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics